Johnson & Johnson receives Canadian approval for Rybrevant in first-line NSCLC
2024-07-03
Mohammed Haneefa Nizamudeen Health Canada has authorized Johnson & Johnson’s (NYSE:JNJ) Rybrevant (amivantamab) along with platinum-based chemotherapy as a first-line treatment for non-small cell lung with a certain mutation. The authorization is for patients with EGFR Exon 20 insertion mutations. The approval was supported by data from the phase 3Continue Reading